Intervention not reported
BEV_RT (1 RCT; 75 participants) · elderly people with newly diagnosed glioblastoma Interventions: chemoradiotherapy (CRT); chemoradiotherapy plus bevacizumab (BEV_CRT);…
The intervention showed no clear difference in BEV_RT (1 RCT; 75 participants) (low certainty).
1 finding from 1 review
Prostate cancer‐specific death5
It is very uncertain whether whole gland primary cryotherapy changes time to death from prostate cancer (absolute effects:… compared with external beam radiotherapy (EBRT) (very low certainty).
1 finding from 1 review
Quality of life ‐ urinary function
1 finding from 1 review
Quality of life ‐ bowel function
1 finding from 1 review
Quality of life ‐ sexual function
1 finding from 1 review
Major adverse events
It is very uncertain whether whole gland primary cryotherapy changes major adverse events compared with external beam radiotherapy (EBRT) (very low certainty).
1 finding from 1 review
Time to death from any cause (absolute effects: overall mortality)
It is very uncertain whether whole gland primary cryotherapy changes time to death from any cause (absolute effects: overall mortality) compared with external beam radiotherapy (EBRT) (very low certainty).
1 finding from 1 review
Secondary interventions for treatment failure ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Interruptions to cancer treatment · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in interruptions to cancer treatment compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Normalcy of diet (percutaneous endoscopic gastrostomy) · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in normalcy of diet (percutaneous endoscopic gastrostomy) compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (severe) compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (moderate to severe) compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Physical fitness · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Fatigue · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Cancer‐specific quality of life · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review